PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice
- 24 December 2004
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
- Vol. 1739 (1) , 70-80
- https://doi.org/10.1016/j.bbadis.2004.09.001
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with -thalassemia majorAnnals of Hematology, 2004
- Purging iron from the heartBritish Journal of Haematology, 2004
- Safety and effectiveness of long-term therapy with the oral iron chelator deferiproneBlood, 2003
- β-Thalassaemia: emergence of new and improved iron chelators for treatmentThe International Journal of Biochemistry & Cell Biology, 2003
- Benefits and Risks of Deferiprone in Iron Overload in Thalassaemia and Other ConditionsDrug Safety, 2003
- Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemiaThe Lancet, 2002
- Deferiprone versus Deferoxamine in Patients with Thalassemia Major: A Randomized Clinical TrialBlood Cells, Molecules, and Diseases, 2002
- The controversial role of deferiprone in the treatment of thalassemiaJournal of Laboratory and Clinical Medicine, 2001
- Long-Term Safety and Effectiveness of Iron-Chelation Therapy with Deferiprone for Thalassemia MajorNew England Journal of Medicine, 1998
- Long-Term Trial of Deferiprone in 51 Transfusion-Dependent Iron Overloaded PatientsBlood, 1998